<DOC>
	<DOCNO>NCT00532961</DOCNO>
	<brief_summary>Phase IV , randomize , double-masked , parallel-group clinical trial compare ocular tolerability steroid-induced intraocular pressure ( IOP ) effect Zylet wth TobraDex healthy volunteer , either product administer QID ( approximately 4-hour interval ) 28 day .</brief_summary>
	<brief_title>Ocular Tolerance Intraocular Pressure ( IOP ) Effects Zylet Versus Tobradex</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>good general health base investigator judgment able willing follow instruction , provide inform consent , make require study visit , use electronic patient diary study possess best correct visual acuity least 20/40 eye female , use reliable contraception negative urine pregnancy test prior study entry contact lenses wear within 30 day prior enrollment study period know hypersensitivity study medication component presence significant ocular systemic disease might interfere interpretation result need administration chronic topical ocular systemic medication kind study . participation opthalmic drug device research study within 30 day prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>